A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans
about
Status of hepatitis C virus vaccination: Recent updateHepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignHepatitis C virus: Virology, diagnosis and treatmentImmunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virusCapitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine designThe core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigsProtective immunity against hepatitis C: many shades of gray.Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development.Designing and Development of a DNA Vaccine Based On Structural Proteins of Hepatitis C VirusRecombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.Will there be a vaccine to prevent HCV infection?Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77.The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526.Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, ChallengeApplying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activityPrevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallateImmunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex.Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.Progress towards a hepatitis C virus vaccine.The past, present and future of neutralizing antibodies for hepatitis C virus.Vaccination against infectious diseases: what is promising?Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies.HCV glycoprotein structures: what to expect from the unexpected.An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry.Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.Designing an HCV vaccine: a unique convergence of prevention and therapy?Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.Structure-function analysis of hepatitis C virus envelope glycoproteins E1 and E2.Novel E2 Glycoprotein Tetramer Detects Hepatitis C Virus-Specific Memory B Cells.Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.1st Workshop of the Canadian Society for Virology.The Second Canadian Symposium on hepatitis C virus: a call to action.
P2860
Q26774612-71D85232-46C0-4467-AE4A-C62CDE18BD2BQ26799141-1F5B301F-1E49-4A35-B839-902E0F41AFC9Q26801759-B311B98B-F939-47C7-848E-402878DECCA6Q28082000-7E582F07-9140-45E8-BE4A-AF468F480C79Q28604286-F2781848-44F9-4DB0-B49A-D6937AC1D6C0Q30374314-09000E78-52B9-460A-A707-4EE0E90CF5BDQ33612608-B27E7763-6B5A-4442-B72C-C67BD078639BQ33759224-D3A408F6-12DD-4C61-96E7-0C7DB2D9FF1AQ33890011-E15560C4-8BCC-4D9B-957F-9A093923CB32Q34262165-F0DD60CF-78F7-4829-9997-F3D3943D3E33Q34481429-6CA611D6-91E0-4B03-9641-194A62EEE767Q34543833-BFE7F1CC-8598-41A2-9C33-A7C7BB1ACAD4Q34594986-69BC983B-8AB2-4BD6-9088-3370C592E1C0Q34781537-950240D2-17E4-43EF-BC94-5B7BE3118214Q34992715-C99C61E2-EBD1-4BAC-91B5-BF3BB930F06EQ35750560-21C3F607-AE49-43EC-BF5F-D2CB00F9E0A3Q35912053-B2B7468D-0C53-4C33-B967-DDD96F24774AQ35913863-CD18A1C0-EF2C-4C93-86E5-A85C36A8F81BQ36288404-8A482949-46D0-428E-8949-878B72284C44Q36378193-5E61E67C-B637-4DE3-801B-01C66FA7318BQ36624431-360B0B74-5732-4250-B912-6A96B62FFF97Q37144953-631DB501-431E-4158-93A5-7B3B7204079EQ37415463-33C482EE-C45C-41EE-A8AE-CF0FAD44DC05Q37512845-782AF0E3-AF2E-4E3F-BA6A-51548784F0B7Q37584338-8A632321-F132-41FC-832E-F93E42CBE732Q38192357-EE9E45E5-40B5-4FC4-A678-73BF6D61502EQ38234231-F1070DFD-4EB1-45E5-972D-1E4D4E207807Q38234934-76ED41C3-8776-4747-98AE-A02A58A1A3DEQ38384140-B566447A-3C03-49BF-89AF-8A453E0D2874Q38723923-4E2D2B53-DD24-46E0-BCE0-C41C204AD9D9Q38856649-1778781A-08CC-401F-B1AF-E42674F8D64AQ39333862-213F5BB1-B95D-4AE1-8311-6B22FBCC1B25Q39483891-4311DCA5-D250-413C-87F0-9950970179D9Q40189989-1BD38125-47B7-40E9-90FB-9E27BD51A78AQ40449975-363C3209-F4B2-474F-AF7B-D1C5218EDD85Q40634075-8E4DAEBB-BF7E-4E1F-A23C-FB403C7F7A1EQ40736300-0738CAB8-80D1-4E7A-991E-B5E5A96AF474Q41672361-77533A57-BFE0-406D-9B49-4EFFD58D4FFCQ42370476-C59E31D3-A02A-4656-A938-4A0F49682552Q42922380-B2C3DC47-64A0-4294-91C0-13E0C709C6DA
P2860
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A hepatitis C virus (HCV) vacc ...... tralizing antibodies in humans
@ast
A hepatitis C virus (HCV) vacc ...... tralizing antibodies in humans
@en
A hepatitis C virus (HCV) vacc ...... tralizing antibodies in humans
@nl
type
label
A hepatitis C virus (HCV) vacc ...... tralizing antibodies in humans
@ast
A hepatitis C virus (HCV) vacc ...... tralizing antibodies in humans
@en
A hepatitis C virus (HCV) vacc ...... tralizing antibodies in humans
@nl
prefLabel
A hepatitis C virus (HCV) vacc ...... tralizing antibodies in humans
@ast
A hepatitis C virus (HCV) vacc ...... tralizing antibodies in humans
@en
A hepatitis C virus (HCV) vacc ...... tralizing antibodies in humans
@nl
P2093
P2860
P50
P3181
P1433
P1476
A hepatitis C virus (HCV) vacc ...... tralizing antibodies in humans
@en
P2093
Charles M Rice
Christopher T Jones
D Lorne Tyrrell
Darren Hockman
Deanna M Santer
Jason Wong
John Lok Man Law
Michael Houghton
Sharon E Frey
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0059776
P407
P577
2013-01-01T00:00:00Z